1
|
Gajra A, Ali H, Amiri KI, Karim NA, Matrana MR, Mulford D, Ong TJ, Sanford A, Santos ES, Socinski MA, Spigel DR. PS01.08: ABOUND.PS2 Interim Safety Results: nab -Paclitaxel/Carboplatin Followed by nab -Paclitaxel in NSCLC Patients with ECOG PS of 2. J Thorac Oncol 2016. [DOI: 10.1016/j.jtho.2016.09.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
Langer C, Hirsh V, Amiri KI, Ko A, Knoble J, Johnson M, Jotte R, Mccleod M, Ong TJ, Page R, Spigel D, West HJ, Trunova N. P1.47: ABOUND.sqm QoL by Response: Interim Analysis of Squamous NSCLC Pts Treated With nab-Paclitaxel/Carboplatin Induction Therapy. J Thorac Oncol 2016. [DOI: 10.1016/j.jtho.2016.08.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
3
|
Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. EMBO Mol Med 2013; 5:149-66. [PMID: 23180582 PMCID: PMC3569660 DOI: 10.1002/emmm.201201378] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2012] [Revised: 10/08/2012] [Accepted: 10/11/2012] [Indexed: 01/07/2023] Open
Abstract
Oncogene-induced senescence can provide a protective mechanism against tumour progression. However, production of cytokines and growth factors by senescent cells may contribute to tumour development. Thus, it is unclear whether induction of senescence represents a viable therapeutic approach. Here, using a mouse model with orthotopic implantation of metastatic melanoma tumours taken from 19 patients, we observed that targeting aurora kinases with MLN8054/MLN8237 impaired mitosis, induced senescence and markedly blocked proliferation in patient tumour implants. Importantly, when a subset of tumour-bearing mice were monitored for tumour progression after pausing MLN8054 treatment, 50% of the tumours did not progress over a 12-month period. Mechanistic analyses revealed that inhibition of aurora kinases induced polyploidy and the ATM/Chk2 DNA damage response, which mediated senescence and a NF-κB-related, senescence-associated secretory phenotype (SASP). Blockade of IKKβ/NF-κB led to reversal of MLN8237-induced senescence and SASP. Results demonstrate that removal of senescent tumour cells by infiltrating myeloid cells is crucial for inhibition of tumour re-growth. Altogether, these data demonstrate that induction of senescence, coupled with immune surveillance, can limit melanoma growth.
Collapse
Affiliation(s)
- Yan Liu
- Department of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Oriana E Hawkins
- Department of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Yingjun Su
- Department of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Anna E Vilgelm
- Department of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Tammy Sobolik
- Department of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Yee-Mon Thu
- Department of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Sara Kantrow
- Division of Dermatology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Ryan C Splittgerber
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Sarah Short
- Department of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | - Katayoun I Amiri
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| | | | - Jeffery A Sosman
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical CenterNashville, TN, USA
| | - Mark C Kelley
- Division of Surgical Oncology, Department of Surgery, Vanderbilt University School of MedicineNashville, TN, USA
| | - Ann Richmond
- Department of Veterans Affairs, Tennessee Valley Healthcare SystemNashville, TN, USA
- Department of Cancer Biology, Vanderbilt University Medical CenterNashville, TN, USA
| |
Collapse
|
4
|
Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res 2012; 18:2184-98. [PMID: 22351689 PMCID: PMC3724517 DOI: 10.1158/1078-0432.ccr-11-1122] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
PURPOSE The purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for treatment of human metastatic melanoma and to characterize traits associated with drug response. EXPERIMENTAL DESIGN Advanced metastatic melanoma tumors from 34 patients were orthotopically implanted to nude mice. Tumors that grew in mice (17 of 34) were evaluated for response to RAF265 (40 mg/kg, every day) over 30 days. The relation between patient characteristics, gene mutation profile, global gene expression profile, and RAF265 effects on tumor growth, mitogen-activated protein/extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) phosphorylation, proliferation, and apoptosis markers was evaluated. RESULTS Nine of the 17 tumors that successfully implanted (53%) were mutant BRAF (BRAF(V600E/K)), whereas eight of 17 (47%) tumors were BRAF wild type (BRAF(WT)). Tumor implants from 7 of 17 patients (41%) responded to RAF265 treatment with more than 50% reduction in tumor growth. Five of the 7 (71%) responders were BRAF(WT), of which 1 carried c-KIT(L576P) and another N-RAS(Q61R) mutation, while only 2 (29%) of the responding tumors were BRAF(V600E/K). Gene expression microarray data from nonimplanted tumors revealed that responders exhibited enriched expression of genes involved in cell growth, proliferation, development, cell signaling, gene expression, and cancer pathways. Although response to RAF265 did not correlate with pERK1/2 reduction, RAF265 responders did exhibit reduced pMEK1, reduced proliferation based upon reduced Ki-67, cyclin D1 and polo-like kinase1 levels, and induction of the apoptosis mediator BCL2-like 11. CONCLUSIONS Orthotopic implants of patient tumors in mice may predict prognosis and treatment response for melanoma patients. A subpopulation of human melanoma tumors responds to RAF265 and can be characterized by gene mutation and gene expression profiles.
Collapse
Affiliation(s)
- Yingjun Su
- Department of Veterans Affairs
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | - Anna E. Vilgelm
- Department of Veterans Affairs
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | | | - Oriana E. Hawkins
- Department of Veterans Affairs
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | - Yan Liu
- Department of Veterans Affairs
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | - Kelli L. Boyd
- Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine
| | | | | | - Sarah P. Short
- Department of Veterans Affairs
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | - Tammy Sobolik
- Department of Veterans Affairs
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | - Snjezana Zaja-Milatovic
- Department of Veterans Affairs
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | - Kimberly Brown Dahlman
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | - Katayoun I. Amiri
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| | - Aixiang Jiang
- Division of Cancer Biostatistics, Department of Biostatistics, Vanderbilt University Medical Center
| | - Pengcheng Lu
- Division of Cancer Biostatistics, Department of Biostatistics, Vanderbilt University Medical Center
| | - Yu Shyr
- Division of Cancer Biostatistics, Department of Biostatistics, Vanderbilt University Medical Center
| | - Darrin D. Stuart
- Novartis Institutes for Biomedical Research, Emeryville, California
| | - Shawn Levy
- Department of Biochemistry, Vanderbilt University School of Medicine
| | - Jeffrey A. Sosman
- Division of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Ann Richmond
- Department of Veterans Affairs
- Department of Cancer Biology, Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine
| |
Collapse
|
5
|
Harry SR, Hicks DJ, Amiri KI, Wright DW. Hairpin DNA coated gold nanoparticles as intracellular mRNA probes for the detection of tyrosinase gene expression in melanoma cells. Chem Commun (Camb) 2010; 46:5557-9. [PMID: 20526488 DOI: 10.1039/c001969k] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A new intracellular mRNA imaging probe has been developed that incorporates thiol-terminated hairpin oligonucleotides covalently bound to the surface of citrate-capped gold nanoparticles. The hairpin DNA-coated gold nanoparticles (hAuNPs) positively identifies tyrosinase mRNA in cultured melanoma cells.
Collapse
Affiliation(s)
- S Reese Harry
- Department of Chemistry, Vanderbilt University, Station B351822, Nashville, TN 37235, USA
| | | | | | | |
Collapse
|
6
|
Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res 2009; 16:348-57. [PMID: 20028756 DOI: 10.1158/1078-0432.ccr-09-2087] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE Preclinical studies show that bortezomib, a proteasome inhibitor, blocks NF-kappaB activation and, combined with temozolomide, enhances activity against human melanoma xenografts and modulates other critical tumor targets. We initiated a phase I trial of temozolomide plus bortezomib in advanced melanoma. Objectives included defining a maximum tolerated dose for the combination, characterizing biomarker changes reflecting inhibition of both proteasome and NF-kappaB activity in blood (if possible tumor), and characterizing antitumor activity. EXPERIMENTAL DESIGN Cohorts were enrolled onto escalating dose levels of temozolomide (50-75 mg/m(2)) daily, orally, for 6 of 9 weeks and bortezomib (0.75-1.5 mg/m(2)) by i.v. push on days 1, 4, 8, and 11 every 21 days. Peripheral blood mononuclear cells were assayed at specified time points for proteasome inhibition and NF-kappaB biomarker activity. RESULTS Bortezomib (1.3 mg/m(2)) and temozolomide (75 mg/m(2)) proved to be the maximum tolerated dose. Dose-limiting toxicities included neurotoxicity, fatigue, diarrhea, and rash. Nineteen melanoma patients were enrolled onto four dose levels. This melanoma population (17 M1c, 10 elevated lactate dehydrogenase, 12 performance status 1-2) showed only one partial response (8 months) and three with stable disease >or=4 months. A significant reduction in proteasome-specific activity was observed 1 hour after infusion at all bortezomib doses. Changes in NF-kappaB electrophoretic mobility shift assay and circulating chemokines in blood failed to correlate with the schedule/dose of bortezomib, inhibition of proteasome activity, or clinical outcome. CONCLUSIONS We have defined phase II doses for this schedule of temozolomide with bortezomib. Although proteasome activity was inhibited for a limited time in peripheral blood mononuclear cells, we were unable to show consistent effects on NF-kappaB activation.
Collapse
Affiliation(s)
- Yingjun Su
- Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee 37027, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 2006; 12:950-60. [PMID: 16467110 PMCID: PMC2668250 DOI: 10.1158/1078-0432.ccr-05-1220] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Constitutive activation of inhibitor of kappaB kinase (IKK) confers melanoma resistance to apoptosis and chemotherapy. Whether IKK is able to serve as a therapeutic target in melanoma is unknown. We explored the possibility of exploiting IKK as a therapeutic target in melanoma by using BMS-345541, a novel compound with a highly selective IKKbeta inhibitory activity, to trigger melanoma cell apoptosis. EXPERIMENTAL DESIGN Three human melanoma cell lines (SK-MEL-5, Hs 294T, and A375), all of which have high constitutive IKK activities, served as in vitro and in vivo melanoma models for treatment with BMS-345541. Two known antitumor drugs (temozolomide and bortezomib) were used as parallel controls for evaluation of the therapeutic efficiency and toxicity of BMS-345541. The effects of BMS-345541 on nuclear factor kappaB (NF-kappaB) signaling and on the apoptosis machinery were investigated. RESULTS Inhibition of constitutive IKK activity by BMS-345541 resulted in the reduction of NF-kappaB activity, CXCL1 chemokine secretion by cultured melanoma cells and melanoma cell survival in vitro and in vivo. The effect of BMS-345541 on tumor cell growth was through mitochondria-mediated apoptosis, based on the release of apoptosis-inducing factor, dissipation of mitochondrial membrane potential, and reduced ratio of B cell lymphoma gene-2 (Bcl-2)/Bcl-associated X protein (Bax) in mitochondria. The BMS-345541 execution of apoptosis was apoptosis-inducing factor-dependent, but largely caspase-independent. CONCLUSION BMS-345541 down-regulation of IKK activity results in mitochondria-mediated apoptosis of tumor cells because the programmed cell death machinery in melanoma cells is highly regulated by NF-kappaB signaling. Therefore, IKK may serve as a potential target for melanoma therapy.
Collapse
Affiliation(s)
- Jinming Yang
- Veterans Affairs Medical Center and Department of Cancer Biology, Vanderbilt University School of Medicine
| | - Katayoun I. Amiri
- Veterans Affairs Medical Center and Department of Cancer Biology, Vanderbilt University School of Medicine
- Meharry Medical College, Nashville, Tennessee
| | - James R. Burke
- Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey
| | - Johannes A. Schmid
- Department of Vascular Biology and Thrombosis Research, University of Vienna Medical School, Vienna, Austria
| | - Ann Richmond
- Veterans Affairs Medical Center and Department of Cancer Biology, Vanderbilt University School of Medicine
| |
Collapse
|
8
|
Abstract
The continuous production of the CXC ligand 1 (CXCL1) chemokine by melanoma cells is a major effector of tumor growth. We have previously shown that the constitutive expression of this chemokine is dependent upon transcription factors nuclear factor-kappa B (NF-kappaB), stimulating protein-1 (SP1), high-mobility group-I/Y (HMGI/Y), CAAT displacement protein (CDP) and poly(ADP-ribose) polymerase-1 (PARP-1). In this study, we demonstrate for the first time the mechanism of transcriptional regulation of CXCL1 through PARP-1 in melanoma cells. In its inactive state, PARP-1 binds to the CXCL1 promoter in a sequence-specific manner and prevents binding of NF-kappaB (p65/p50) to its element. However, activation of the PARP-1 enzymatic activity enhances CXCL1 expression, owing to the loss of PARP-1 binding to the CXCL1 promoter, accompanied by enhanced binding of p65 to the promoter. The delineation of the role of NF-kappaB-interacting factors in the putative CXCL1 enhanceosome will provide key information in developing strategies to block constitutive expression of this and other chemokines in cancer and to develop targeted therapy.
Collapse
Affiliation(s)
- KI Amiri
- Department of Veterans Affairs, Vanderbilt University School of Medicine, Nashville, TN, USA
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
- Department of Microbiology, Meharry Medical College, Nashville, TN, USA
| | - HC Ha
- Department of Biochemistry and Molecular Biology, Georgetown University School of Medicine, Washington, DC, USA
| | - ME Smulson
- Department of Biochemistry and Molecular Biology, Georgetown University School of Medicine, Washington, DC, USA
| | - A Richmond
- Department of Veterans Affairs, Vanderbilt University School of Medicine, Nashville, TN, USA
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
| |
Collapse
|
9
|
Abstract
Nuclear Factor-kappa B (NF-kappa B) is an inducible transcription factor that regulates the expression of many genes involved in the immune response. Recently, NF-kappa B activity has been shown to be upregulated in many cancers, including melanoma. Data indicate that the enhanced activation of NF-kappa B may be due to deregulations in upstream signaling pathways such as Ras/Raf, PI3K/Akt, and NIK. Multiple studies have shown that NF-kappa B is involved in the regulation of apoptosis, angiogenesis, and tumor cell invasion, all of which indicate the important role of NF-kappa B in tumorigenesis. Thus, understanding the molecular mechanism of melanoma progression will aid in designing new therapeutic approaches for melanoma. In this review, the association between NF-kappa B and melanoma tumorigenesis are discussed. Additionally, the potential of emerging selective NF-kappa B inhibitors for the treatment of melanoma is reviewed.
Collapse
|
10
|
Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004; 64:4912-8. [PMID: 15256463 DOI: 10.1158/0008-5472.can-04-0673] [Citation(s) in RCA: 122] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Melanoma poses a great challenge to patients, oncologists, and biologists because of its nearly universal resistance to chemotherapy. Many studies have shown that nuclear factor kappaB is constitutively activated in melanoma, thereby promoting the proliferation of melanoma cells by inhibiting the apoptotic responses to chemotherapy. Nuclear factor kappaB activity is regulated by phosphorylation and subsequent degradation of inhibitor of nuclear factor kappaB by the ubiquitin-proteasome pathway. In this study, we show that the novel proteasome inhibitor, bortezomib, inhibited the growth of melanoma cells in vitro at a concentration range of 0.1-10 nM and in combination with the chemotherapeutic agent temozolomide, the inhibitory effect on melanoma cell growth was even more prominent. Data from a murine model showed reduced tumor growth when bortezomib was administered to human melanoma tumors. Strikingly, animals receiving bortezomib in combination with temozolomide achieved complete remission of palpable tumors after only 30 days of therapy, lasting >200 days. Our data indicate strongly that bortezomib in combination with chemotherapeutic agents should be studied additionally for the treatment of melanoma.
Collapse
Affiliation(s)
- Katayoun I Amiri
- Department of Veterans Affairs, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | | | | | | | | |
Collapse
|